Brian C Tse1, Fariba Navid2, Catherine A Billups3, Thomas O'Donnell1, Mary E Hoehn4. 1. Department of Ophthalmology, Hamilton Eye Institute, University of Tennessee Health Science Center, Memphis, Tennessee; Department of Surgery, Division of Ophthalmology, St. Jude Children's Research Hospital, Memphis, Tennessee. 2. Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee; Department of Pediatrics, College of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee. 3. Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee. 4. Department of Ophthalmology, Hamilton Eye Institute, University of Tennessee Health Science Center, Memphis, Tennessee; Department of Surgery, Division of Ophthalmology, St. Jude Children's Research Hospital, Memphis, Tennessee; Department of Pediatrics, College of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee. Electronic address: mhoehn@uthsc.edu.
Abstract
PURPOSE: To determine the incidence of and factors associated with the development of mydriasis and impaired accommodation in patients with refractory or recurrent neuroblastoma receiving the anti-GD2 antibody hu14.18K322A. METHODS: The medical records of eligible patients with refractory or recurrent neuroblastoma who received escalating doses of hu14.18K322A, ranging from 2 to 70 mg/m(2)/dose for 4 consecutive days every 28 days, were retrospectively reviewed to identify ocular abnormalities arising during the treatment period. RESULTS: A total of 38 patients (median age, 7 years; 23 males) were included. All patients underwent comprehensive eye examinations prior to each course of therapy. Mydriasis was seen in 13 patients (34%), and impaired accommodation was seen in 9 (24%), indicating a dose-related effect between hu14.18K322A and both mydriasis (P = 0.021) and impaired accommodation (P = 0.029). Age and sex were not associated with ocular abnormalities. Ocular symptoms resolved in the majority of patients after the drug was discontinued. CONCLUSIONS: Side effects of mydriasis and impaired accommodation have a dose-dependent relationship with hu14.18K322A. These side effects do not warrant discontinuation of treatment, as they usually resolve after completion of therapy. Management of ocular side effects should focus on treating symptoms with manifest refraction, bifocals, or tinted spectacles.
PURPOSE: To determine the incidence of and factors associated with the development of mydriasis and impaired accommodation in patients with refractory or recurrent neuroblastoma receiving the anti-GD2 antibody hu14.18K322A. METHODS: The medical records of eligible patients with refractory or recurrent neuroblastoma who received escalating doses of hu14.18K322A, ranging from 2 to 70 mg/m(2)/dose for 4 consecutive days every 28 days, were retrospectively reviewed to identify ocular abnormalities arising during the treatment period. RESULTS: A total of 38 patients (median age, 7 years; 23 males) were included. All patients underwent comprehensive eye examinations prior to each course of therapy. Mydriasis was seen in 13 patients (34%), and impaired accommodation was seen in 9 (24%), indicating a dose-related effect between hu14.18K322A and both mydriasis (P = 0.021) and impaired accommodation (P = 0.029). Age and sex were not associated with ocular abnormalities. Ocular symptoms resolved in the majority of patients after the drug was discontinued. CONCLUSIONS: Side effects of mydriasis and impaired accommodation have a dose-dependent relationship with hu14.18K322A. These side effects do not warrant discontinuation of treatment, as they usually resolve after completion of therapy. Management of ocular side effects should focus on treating symptoms with manifest refraction, bifocals, or tinted spectacles.
Authors: Alice L Yu; Andrew L Gilman; M Fevzi Ozkaynak; Wendy B London; Susan G Kreissman; Helen X Chen; Malcolm Smith; Barry Anderson; Judith G Villablanca; Katherine K Matthay; Hiro Shimada; Stephan A Grupp; Robert Seeger; C Patrick Reynolds; Allen Buxton; Ralph A Reisfeld; Steven D Gillies; Susan L Cohn; John M Maris; Paul M Sondel Journal: N Engl J Med Date: 2010-09-30 Impact factor: 91.245
Authors: R Handgretinger; P Baader; R Dopfer; T Klingebiel; P Reuland; J Treuner; R A Reisfeld; D Niethammer Journal: Cancer Immunol Immunother Date: 1992 Impact factor: 6.968
Authors: Fariba Navid; Paul M Sondel; Raymond Barfield; Barry L Shulkin; Robert A Kaufman; Jim A Allay; Jacek Gan; Paul Hutson; Songwon Seo; Kyungmann Kim; Jacob Goldberg; Jacquelyn A Hank; Catherine A Billups; Jianrong Wu; Wayne L Furman; Lisa M McGregor; Mario Otto; Stephen D Gillies; Rupert Handgretinger; Victor M Santana Journal: J Clin Oncol Date: 2014-04-07 Impact factor: 44.544
Authors: M F Ozkaynak; P M Sondel; M D Krailo; J Gan; B Javorsky; R A Reisfeld; K K Matthay; G H Reaman; R C Seeger Journal: J Clin Oncol Date: 2000-12-15 Impact factor: 44.544
Authors: Bernhard Kremens; Barbara Hero; Joachim Esser; Peter Weinel; Judith Filger-Brillinger; Gudrun Fleischhack; Norbert Graf; Hans-Peter Grüttner; Charlotte Niemeyer; Ansgar Schulz; Lutz Wickmann; Frank Berthold Journal: Cancer Immunol Immunother Date: 2002-02-01 Impact factor: 6.968
Authors: Katherine K Matthay; C Patrick Reynolds; Robert C Seeger; Hiroyuki Shimada; E Stanton Adkins; Daphne Haas-Kogan; Robert B Gerbing; Wendy B London; Judith G Villablanca Journal: J Clin Oncol Date: 2009-01-26 Impact factor: 44.544
Authors: A L Yu; M M Uttenreuther-Fischer; C S Huang; C C Tsui; S D Gillies; R A Reisfeld; F H Kung Journal: J Clin Oncol Date: 1998-06 Impact factor: 44.544
Authors: R Handgretinger; K Anderson; P Lang; R Dopfer; T Klingebiel; M Schrappe; P Reuland; S D Gillies; R A Reisfeld; D Neithammer Journal: Eur J Cancer Date: 1995 Impact factor: 9.162
Authors: Alice L Yu; Andrew L Gilman; M Fevzi Ozkaynak; Arlene Naranjo; Mitchell B Diccianni; Jacek Gan; Jacquelyn A Hank; Ayse Batova; Wendy B London; Sheena C Tenney; Malcolm Smith; Barry L Shulkin; Marguerite Parisi; Katherine K Matthay; Susan L Cohn; John M Maris; Rochelle Bagatell; Julie R Park; Paul M Sondel Journal: Clin Cancer Res Date: 2021-01-27 Impact factor: 13.801
Authors: Giuseppe Barone; Ailish Barry; Francisco Bautista; Bénédicte Brichard; Anne-Sophie Defachelles; Fiona Herd; Carla Manzitti; Dirk Reinhardt; Pedro M Rubio; Aleksandra Wieczorek; Max M van Noesel Journal: Paediatr Drugs Date: 2021-09-20 Impact factor: 3.022